Related Experiment Video

Updated: Jul 11, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Future options for imatinib mesilate-resistant tumors

Kamalesh K Sankhala1, Kyriakos P Papadopoulos

  • 1Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA.

Expert Opinion on Investigational Drugs
|October 10, 2007
PubMed

Insights

Imatinib therapy improves outcomes for gastrointestinal stromal tumors (GIST), but resistance develops. New therapies and combination strategies targeting KIT and PDGF receptor mutations offer hope for overcoming imatinib resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastrointestinal stromal tumors (GIST) treatment significantly improved with imatinib mesilate, a KIT and PDGFR tyrosine kinase inhibitor.
  • Most patients develop resistance to imatinib, leading to disease progression.
  • Understanding resistance mechanisms, like secondary mutations in KIT and PDGF receptors, is crucial for new therapies.

Purpose of the Study:

  • To review the efficacy of sunitinib in imatinib-resistant GIST.
  • To highlight emerging second-generation tyrosine kinase inhibitors for imatinib-resistant GIST.
  • To discuss strategies for overcoming imatinib resistance, including combination therapy and mutation-specific treatments.

Main Methods:

  • Review of current literature on imatinib resistance in GIST.
  • Analysis of clinical data for sunitinib and other emerging therapies.
  • Discussion of molecular mechanisms of resistance and targeted treatment strategies.

Main Results:

  • Sunitinib is approved for imatinib-resistant GIST.
  • Several novel kinase inhibitors show promise in preclinical and clinical studies.
  • Targeting downstream pathways and optimizing combination therapies are viable strategies.

Conclusions:

  • Advances in understanding imatinib resistance mechanisms are driving the development of next-generation therapies.
  • Personalized treatment approaches, guided by specific tumor mutations, are essential for managing imatinib-resistant GIST.
  • Future strategies involve combination therapies and novel agents targeting resistant kinase mutations.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...